PD
SAGE

Point72 (DIFC)’s Sage Therapeutics SAGE Stock Holding History

Point72 (DIFC)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,852
Closed -$70.4K – 2026
2025
Q1 		$70.4K Buy
8,852
+3,833
+76% +$28.1K ﹤0.01% 1144
2024
Q4 		$27.3K Buy
+5,019
New +$30.7K ﹤0.01% 1215
2024
Q3 		– Sell
-14,097
Closed -$153K – 1777
2024
Q2 		$153K Buy
+14,097
New +$181K 0.01% 905

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Point72 (DIFC)'s SAGE Position: Q2 2025 in Review

Point72 (DIFC) sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 8,852 shares — an estimated $70.4K sold.

Point72 (DIFC) first reported a position in SAGE in Q2 2024 and held it in 3 quarters. The position peaked at $153K in Q2 2024. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Point72 (DIFC) reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 8,852 Sage Therapeutics shares in Q2 2025, an estimated $70.4K.
  • Point72 (DIFC) first reported a position in Sage Therapeutics in Q2 2024 and held it in 3 quarters.
  • Point72 (DIFC)'s Sage Therapeutics position peaked at $153K in Q2 2024.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.